Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,059,291
  • Shares Outstanding, K 127,054
  • Annual Sales, $ 829,250 K
  • Annual Income, $ 281,590 K
  • 60-Month Beta 1.26
  • Price/Sales 6.02
  • Price/Cash Flow 11.99
  • Price/Book 60.05
Trade HALO with:

Options Overview Details

View History
  • Implied Volatility 51.38% ( +10.14%)
  • Historical Volatility 23.48%
  • IV Percentile 94%
  • IV Rank 73.48%
  • IV High 58.43% on 10/27/23
  • IV Low 31.85% on 11/28/23
  • Put/Call Vol Ratio 0.24
  • Today's Volume 26
  • Volume Avg (30-Day) 187
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 7,091
  • Open Int (30-Day) 7,495

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.64
  • Number of Estimates 5
  • High Estimate 0.71
  • Low Estimate 0.58
  • Prior Year 0.43
  • Growth Rate Est. (year over year) +48.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.73 +5.78%
on 04/19/24
41.50 -3.83%
on 04/05/24
-0.32 (-0.80%)
since 04/03/24
3-Month
33.15 +20.39%
on 02/05/24
42.64 -6.40%
on 03/13/24
+6.23 (+18.50%)
since 02/02/24
52-Week
29.85 +33.70%
on 05/09/23
45.00 -11.31%
on 08/10/23
+7.51 (+23.18%)
since 05/03/23

Most Recent Stories

More News
Halozyme Therapeutics: Q4 Earnings Snapshot

Halozyme Therapeutics: Q4 Earnings Snapshot

HALO : 39.91 (+0.23%)
Plexus, SunPower fall; Progress Software, Masonite International rise, Wednesday, 1/17/2024

Stocks that traded heavily or had substantial price changes on Wednesday: Plexus, SunPower fall; Progress Software, Masonite International rise

PLXS : 104.07 (+0.66%)
SPWR : 2.34 (+7.34%)
BGFV : 3.41 (+1.19%)
PRGS : 50.51 (+0.14%)
HALO : 39.91 (+0.23%)
PI : 161.23 (+0.94%)
DOOR : 132.70 (unch)
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond

Healthcare stocks have underperformed in 2023, but that is expected to change this year.

CNC : 74.81 (+0.65%)
HALO : 39.91 (+0.23%)
ABCL : 4.03 (+4.68%)
HUM : 320.54 (-0.14%)
Halozyme Therapeutics: Q3 Earnings Snapshot

Halozyme Therapeutics: Q3 Earnings Snapshot

HALO : 39.91 (+0.23%)
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb (BMS) reported positive topline results from...

HALO : 39.91 (+0.23%)
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") will present the positive results of a clinical study demonstrating subcutaneous...

HALO : 39.91 (+0.23%)
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's...

HALO : 39.91 (+0.23%)
Betting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your Radar

Following a tumultuous performance year, the biotechnology sector is steadily regaining traction once again, with investors starting to reveal a somewhat bullish sentiment despite having to endure macroeconomic...

HALO : 39.91 (+0.23%)
KNSA : 20.08 (+3.61%)
ACAD : 17.05 (-0.18%)
HRMY : 31.57 (-0.38%)
AMPH : 42.46 (-0.47%)
INCY : 53.76 (+1.26%)
AGEN : 13.07 (+4.39%)
NVS : 97.27 (-0.07%)
PFE : 27.81 (+0.40%)
SGEN : 228.74 (-0.07%)
MRK : 127.51 (-0.58%)
RXDX : 199.92 (+0.09%)
Halozyme Therapeutics: Q2 Earnings Snapshot

Halozyme Therapeutics: Q2 Earnings Snapshot

HALO : 39.91 (+0.23%)
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second...

HALO : 39.91 (+0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 41.45
2nd Resistance Point 41.10
1st Resistance Point 40.50
Last Price 39.91
1st Support Level 39.55
2nd Support Level 39.20
3rd Support Level 38.60

See More

52-Week High 45.00
Last Price 39.91
Fibonacci 61.8% 39.21
Fibonacci 50% 37.42
Fibonacci 38.2% 35.64
52-Week Low 29.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar